Skip to main content

Table 4 Incidence of adverse reactions

From: Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1

  Group 1a
(n = 57)
Group 2b
(n = 221)
Group 3c
(n = 58)
Group 4d
(n = 107)
P
Nausea 26 113 26 46 0.518
Vomit 4 30 5 7 0.172
Abdominal pain 27 87 26 52 0.385
Fever 9 32 20 26 0.003
Acute liver failure 1 0 0 1 0.079
Liver abscess 1 2 1 1 0.915
  1. aGroup 1: normal-weight patients without HBV
  2. bGroup 2: normal-weight patients combined HBV
  3. cGroup 3: overweight patients without HBV
  4. dGroup 4: overweight patients combined HBV